$3.42
3.51%
Downside
Day's Volatility :4.35%
Upside
0.87%
87.43%
Downside
52 Weeks Volatility :94.31%
Upside
54.76%
Period | Dare Bioscience Inc | Index (Russel 2000) |
---|---|---|
3 Months | -45.19% | 0.0% |
6 Months | -42.19% | 0.0% |
1 Year | -53.88% | 0.0% |
3 Years | -83.53% | -22.3% |
Market Capitalization | 29.5M |
Book Value | $0.31 |
Earnings Per Share (EPS) | 32.28 |
PE Ratio | 0.11 |
PEG Ratio | 0.0 |
Wall Street Target Price | 20.33 |
Profit Margin | -253.6% |
Operating Margin TTM | -32799.12% |
Return On Assets TTM | -71.42% |
Return On Equity TTM | -994.69% |
Revenue TTM | 2.8M |
Revenue Per Share TTM | 0.36 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 9.9M |
EBITDA | -26.7M |
Diluted Eps TTM | 32.28 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.67 |
EPS Estimate Next Year | -1.36 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | -0.69 |
What analysts predicted
Upside of 494.44%
Sell
Neutral
Buy
Dare Bioscience Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Dare Bioscience Inc | 6.54% | -42.19% | -53.88% | -83.53% | -63.47% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Dare Bioscience Inc | 0.11 | 0.11 | 0.0 | -0.67 | -9.95 | -0.71 | NA | 0.31 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Dare Bioscience Inc | Buy | $29.5M | -63.47% | 0.11 | -253.6% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Dare Bioscience Inc
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 91.0%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 152.7%
Vanguard Group Inc
Geode Capital Management, LLC
Renaissance Technologies Corp
BlackRock Inc
State Street Corporation
Northern Trust Corp
daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.
Organization | Dare Bioscience Inc |
Employees | 23 |
CEO | Ms. Sabrina Martucci Johnson |
Industry | Health Technology |
A Spac I Acquisition Corp
$3.42
-0.87%
Keyarch Acquisition Corp
$3.42
-0.87%
Connexa Sports Technologies Inc
$3.42
-0.87%
Us Value Etf
$3.42
-0.87%
First Wave Biopharma Inc
$3.42
-0.87%
Global X Msci Next Emerging
$3.42
-0.87%
Fat Projects Acquisition Corp
$3.42
-0.87%
Capital Link Global Fintech
$3.42
-0.87%
Applied Uv Inc
$3.42
-0.87%